OMCL250117C65000
- 0.40
- 0.000.00%
Omnicell Newsroom
Omnicell Is Maintained at Neutral by B of A Securities
Omnicell Price Target Cut to $46.00/Share From $54.00 by B of A Securities
Omnicell Analyst Ratings
BofA Securities Maintains Omnicell(OMCL.US) With Hold Rating, Cuts Target Price to $46
Express News | Omnicell Inc : BofA Global Research Cuts Price Objective to $46 From $54
Omnicell Gains 26.2% in a Year: What's Driving the Stock?
Omnicell, Inc.'s (NASDAQ:OMCL) Shares Lagging The Industry But So Is The Business
Cautious Outlook on Omnicell: Hold Rating Due to Uncertain Robotic Revenue Growth Amid Job Fluctuations
How Humanoid Robots and AI Will Change the Workforce
Here's Why You Should Add HAE Stock to Your Portfolio Now
Tesla's Optimus is driving a transformation in the Industry, leading humanoid robots into a new era of mass production.
From 0 to 1, humanoid robots are about to enter mass production, and the Industry Chain will embrace investment opportunities.
Omnicell's SWOT Analysis: Healthcare Tech Firm's Stock Faces Growth Hurdles
Omnicell Insider Sold Shares Worth $567,638, According to a Recent SEC Filing
What Makes Omnicell (OMCL) a New Strong Buy Stock
Omnicell Introduces OmniSphere Platform, Stock to Gain
BofA Securities Maintains Omnicell(OMCL.US) With Hold Rating, Maintains Target Price $54
Omnicell Announces OmniSphere, A Next-Generation, Cloud Native, Software Workflow Engine And Data Platform
Piper Sandler Maintains Omnicell(OMCL.US) With Buy Rating, Raises Target Price to $69
The Zacks Analyst Blog Highlights Inspire Medical, Omnicell, Talkspace, Butterfly Network and Clover Health
Will HAE Stock Gain Following Sell-Off of Whole Blood Assets to GVS?